Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.15 SEK | -3.67% | -6.25% | +17.10% |
May. 23 | CombiGene AB Approves Election of Marcus Isaksson as Board Member | CI |
May. 17 | CombiGene AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Number of employees: 8
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Gene Therapies
100.0
%
| 27 | 100.0 % | 6 | 100.0 % | -79.23% |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Sweden
100.0
%
| 27 | 100.0 % | 6 | 100.0 % | -79.23% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Peter Ekolind
CEO | Chief Executive Officer | 60 | 22-09-26 |
Louise Aspenberg
DFI | Director of Finance/CFO | 48 | 20-10-11 |
Daniela Morath
ADM | Chief Administrative Officer | 44 | 17-12-31 |
Karin Agerman
CTO | Chief Tech/Sci/R&D Officer | 51 | 17-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gunilla Lundmark
BRD | Director/Board Member | 61 | 20-12-31 |
Director/Board Member | 59 | 19-12-31 | |
Director/Board Member | 54 | 14-09-30 | |
Per Lundin
BRD | Director/Board Member | 41 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 19,801,197 | 11,880,966 ( 60.00 %) | 0 | 60.00 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+17.10% | 5.86M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- COMBI Stock
- Company CombiGene AB